Interviews with Pharma and Biotech Global Leaders
Refine Search
Biotechnology
Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK. 13 December 2024
Biotechnology
Johnson & Johnson has made significant strides in multiple myeloma treatment, with breakthroughs in targeted therapies like CAR-T and bispecific antibodies. At the 2024 ASH meeting, J&J aims to showcase progress, with a goal of achieving a functional cure for multiple myeloma. 28 November 2024
Pharmaceutical
Germany's Merck has spent more than 25 years researching and developing solutions for advancing multiple sclerosis (MS) care. 21 November 2024
Biotechnology
German biotech CatalYm has followed up a groundbreaking 2023 with an impressive 2024. 19 November 2024
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
Pharmaceutical
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
Pharmaceutical
Plenty of companies in the pharmaceutical industry talk the talk when it comes to focusing on patients. 6 August 2024
Biotechnology
It is not every day that an Italian biotech company raises 23 million euros ($24.7 million) in a Series A financing. 17 June 2024
Pharmaceutical
Privately-held company GAIA has had more than a front-row seat to observe the arrival of digital therapeutics and applications of AI in pharma over the past quarter century. 4 June 2024
Interview
With a steady flow of oncology results emerging from the ongoing ASCO meeting, a company such as Pierre Fabre, which does not have major data to present, might not usually claim the spotlight. 3 June 2024
Biotechnology
Marc de Garidel, chief executive of French clinical-stage biotech Abivax (Nasdaq: ABVX), has good reason for his belief in the company’s pioneering lead asset, obefazimod. 13 May 2024
Pharmaceutical
A Q&A with the man who heads the UK business of the privately-held Italian drugmaker. 3 May 2024
Pharmaceutical
Privately-held Isotope Technologies Munich (ITM) is not just the radiopharmaceutical company that can do it all - from manufacturing and supplying medical radioisotopes to developing a broad precision oncology pipeline, including two Phase III studies. 26 April 2024
Biotechnology
German firm Tubulis has just announced a 128 million euros ($138.8 million) Series B2 financing. 15 March 2024
Pharmaceutical
Staying true to her values is not a secondary consideration for Dr Dennise Broderick in her career and leadership of Galen, but rather is front and central to every action she takes. 7 March 2024
Biotechnology
Since the approval of the first CAR-T in 2017, T cell therapies have revolutionized the treatment of some blood cancers, and are one of the few cancer treatments to drive cures. 12 February 2024
Pharmaceutical
For years, pharmaceutical companies have struggled to develop new treatments for the second most common type of leukemia diagnosed in adults and children, acute myeloid leukemia (AML). 1 March 2018
Pharmaceutical
With 2017 sales growth at 21.5% and shares in the company up 96% since the beginning of last year, everything is going right for Ipsen at the moment. 21 February 2018
Pharmaceutical
Sometimes a device or diagnostic comes along that even the most drug-centric of pharma companies cannot afford to ignore, but when this innovation threatens to establish a new diagnostic modality that sits alongside blood and urine, it is definitely worth taking notice. 16 February 2018
Pharmaceutical
The Pharma Letter speaks to Sjaak Vink, the chief executive of the SocialMedwork, a bold and ambitious start-up that wants to stop borders being a barrier for patients. 26 January 2018
Pharmaceutical
With sales of 97 billion yen ($970 million) for the first half of 2017, a rise of nearly 50% on the previous year, the gastroenterology product Entyvio (vedolizumab) is the best-selling brand of Japanese pharma major Takeda Pharmaceutical. 11 January 2018
Pharmaceutical
This year marks the 350th anniversary of German science and technology group Merck KGaA, a milestone that will remind the industry and wider world that it is the oldest operating pharma company in existence anywhere. 10 January 2018
Pharmaceutical
In today’s world, cheap insults from people in high places – whether justified and evidence-backed or not – can do harm to the reputation and market value of pharma firms that can be difficult to repair. 15 December 2017
Biotechnology
There are a few striking similarities between the world’s biggest biotech firm focused on rare diseases, and an emerging clinical stage pharma company that was set up just a couple of years ago. 5 December 2017
Biotechnology
Mads Krogsgaard Thomsen, Novo Nordisk employee for over a quarter of a century, says he has "been through all the miserable failures as well as the successes of the company, from products that are now off patent to those that don't yet have one." 28 November 2017
Biotechnology
The convergence of two trends makes Chris Claxton, the vice president of investor relations at UK-based Horizon Discovery, believe that his company is in the right place at the right time. 20 November 2017
Biotechnology
Boosted by his firm’s positive Phase III presentation at last week’s ATTR meeting, Alnylam Pharmaceuticals’ EVP of research and development Akshay Vaishnaw won’t commit to saying that regulatory approval is inevitable, but he and president Barry Greene certainly give that impression. 10 November 2017
Biotechnology
An interview with Andrew Obenshain, the head of Europe for the gene therapy company. 6 November 2017
Biotechnology
As with many emerging biotech companies, shares in UK-based Verona Pharma have jumped around a fair bit as markets make their predictions on whether their leading asset is as good as they say it is. 29 October 2017
Pharmaceutical
Nobody is surprised now when pharma companies that are presenting data at scientific conferences choose to focus on real-world evidence (RWE) as much as, or more than, on their results from randomized control trials. 20 October 2017
Pharmaceutical
While the pharmaceutical industry is often regarded as being sluggardly in its embrace of change, opportunities in digital technology appear to be on the rise, and pharma is taking notice. 3 October 2017
Pharmaceutical
The European Commission (EC) approval of a combination involving Kisqali (ribociclib) for a large breast cancer indication last month led a senior executive from Swiss pharma giant Novartis to proclaim that it proved the company’s ‘recognized leadership in cancer research’. 27 September 2017
Biotechnology
While it’s not unheard of to find a biotech firm in the American Mountain States, it is unusual. In the case of Clovis Oncology, the explanation for its location in Colorado is clear, as co-founder and chief executive Pat Mahaffy explains: “I started the firm, and I live here.” 10 September 2017
Biotechnology
As competition in immuno-oncology hots up, in New York, a biotech startup called Rgenix has entered the fray with RGX-104, a small molecule currently entering Phase I. 8 September 2017
Pharmaceutical
News on chimeric antigen receptor T-cell (CAR-T) therapies in the last week has added to the immediacy of a question that has been hanging over these individually-tailored cancer treatments as they have edged closer to market – how on earth are health systems going to afford them? 1 September 2017
Biotechnology
Antony Odell, chief executive of UK-based regenerative medicine company Tissue Regenix, is honest about the industry’s mixed fortunes so far when it comes to turning talk about regenerative medicine into effective products. 25 August 2017
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze